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Available online 03 June 2016To compare pro-inﬂammatory cytokine proﬁles and kinetics in patientswith adult-onset Still's disease (AOSD) to
those in patients with systemic juvenile idiopathic arthritis (s-JIA), we analyzed serum cytokine concentrations
in 33 patients with AOSD and 77 patients with s-JIA and compared them with clinical features. Patients with
AOSD and s-JIA shared a common cytokine proﬁle pattern of a signiﬁcant increase in IL-18. Patients with AOSD
were classiﬁed into two subgroups based on serum IL-6 and IL-18 levels. The number of patients with arthritis
was signiﬁcantly higher in the IL-6-dominant subgroup. The cytokine patterns associated with s-JIA and AOSD
share common features, such as a signiﬁcant and predominant increase in IL-18. Distinct IL-6- and IL-18-based
cytokine proﬁles might be responsible for distinct clinicalmanifestations. The presence of two distinct subgroups
in patients with both diseases further supports the view that s-JIA and AOSD share a disease category.
© 2016 Elsevier Inc. All rights reserved.Keywords:
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Macrophage activation syndromeSystemic juvenile idiopathic arthritis (s-JIA), which was ﬁrst
described in 1897 by the British pediatrician George F. Still, is a systemic
inﬂammatory disorder of unknown etiology characterized by arthritis
and systemic signs, such as spiking fever, skin rash, generalized lymph-
adenopathy, hepatosplenomegaly, and serositis [1]. In 1971, Bywaters
ﬁrst described adult-onset Still's disease (AOSD) and noted that this
condition shared clinical similarities with s-JIA, despite the age of
onset being N16 years [2]. A comparison of the epidemiologies, genetic
backgrounds, clinical presentations, and courses of these diseases
convincingly suggests that s-JIA and AOSD are identical [3–5]. However,
some differences between these disorders have been reported,
including an increased frequency of fever, skin rash, myalgia, sore
throat, weight loss, liver dysfunction, and neutrophilia in AOSD relative
to s-JIA [3,6]. The precise AOSD pathogenesis remains to be elucidated,
and it remains unknown whether s-JIA and AOSD share the same
pathogenesis.A, Systemic juvenile idiopathic
, Interleukin; CRP, C reactive
Soluble tissue necrosis factor-a
killer; Th1 cell, Type 1 helper T
School of Medicine, Institute of
University, 13-1 Takaramachi,
Shimizu).Macrophage activation syndrome (MAS) is a severe, potentially
life-threatening complication of both s-JIA and AOSD [7–9]. MAS occurs
in 7%–10% of patients with s-JIA and 12%–17% of patients with AOSD [9].
The hallmark of MAS is an uncontrolled and dysfunctional immune
response involving the continual activation and expansion of T lympho-
cytes and macrophages, leading to marked hypercytokinemia [10]. This
condition is clinically characterized by fever, hepatosplenomegaly,
lymphadenopathy, a profound decrease in all three blood cell lineages,
liver function dysregulation, intravascular coagulation, and central
nervous system dysfunction [11]. The evaluation of bone marrow from
a patient with MAS reveals the characteristic feature of numerous
morphologically benign macrophages with hemophagocytic activity.
Recent studies have shown that inﬂammatory cytokines, including
interleukin (IL)-1, IL-6, IL-18, interferon (IFN)-γ, and tissue necrosis
factor (TNF)-α play pathogenic roles in the disease processes of both
s-JIA and AOSD [12,13]. Furthermore, biological therapies intended to
block these cytokines yield dramatic effects in patients with s-JIA and
AOSD [14,15]. These ﬁndings suggest that inﬂammatory cytokines
play major roles in the pathogenesis of both diseases.
We previously reported increased serum IL 18 levels in patientswith
active s-JIA [16]. Their levels are further elevated in patients with s-JIA-
related MAS. This increase appears to be condition-characteristic
because although other forms of secondary hemophagocytic
lymphohistiocytosis are associated with high serum IL 18 levels, these
levels are lower than those observed in patients with s-JIA [16–18].
Table 1
Clinical characteristics of patients with active-phase adult-onset Still's disease (AOSD) and
systemic juvenile idiopathic arthritis (s-JIA).
F: female; M: male.
AOSD s-JIA p value
Patients 27 66
Age 48.7 ± 17.3 7.3 ± 5.5 b0.0001
Sex(M/F) 6/21 34/32 0.0114
Physical examination ﬁndings
Rash 19 (70) 47 (71) 1.0000
Lymphadenopathy 12 (44) 23 (35) 0.4804
Hepatomegaly 11 (41) 10 (15) 0.0127
Splenomegaly 9 (33) 8 (12) 0.0351
Arthritis 7 (26) 35 (53) 0.0219
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patients with distinct clinical features and different IL-6/IL-18 ratios
[19]. Serum IL-18 levels are also elevated in patients with AOSD and
can be used as a diagnostic biomarker and therapeutic response indica-
tor [20,21].
We hypothesized that the cytokine release patterns in patients with
s-JIA and AOSD would share common features and that s-JIA and AOSD
belong to the same disease category. To test this hypothesis, we com-
pared the pro-inﬂammatory cytokine proﬁles and cytokine kinetics in
patients with both the active and inactive AOSD with those in patients
with s-JIA. Furthermore, to assess the roles of IL-6 and IL-18 in AOSD
pathogenesis, we analyzed their levels in patients with AOSD and
compared them with the clinical features of AOSD.Laboratory ﬁndings
hyperleukocytosis 20 (74) 52 (79) 0.5984






0.02001. Materials and methods
1.1. Patients and samples
Thirty-three patients with AOSD and 77 patients with s-JIA were in-
cluded in this study. Six of 33 patients with AOSD presented with MAS
at the time of study referral. Twenty of 77 patients with s-JIA presented
withMAS. Eleven of these 20patients presentedwithMAS at the time of
study referral; the other nine patients developed complicating MAS
while in the active disease phase and after starting steroid therapy.
Serum samples from six patients with AOSD and 20 patients with
s-JIA were obtained at the time of MAS diagnosis. Serum samples from
nine of 20 patients with s-JIA were also obtained during the active
phase before developing MAS complication. Serum samples were
obtained from 27 patients with AOSD without MAS and 57 patients
with s-JIA without MAS during the active phase. Serum samples were
also obtained from 13 patients with AOSD and 25 patients with s-JIA
during the inactive phase.
AOSD was diagnosed according to the criteria proposed by
Yamaguchi [22]. s-JIA was diagnosed according to the criteria of the
International League of Associations for Rheumatology [23]. AOSD-
associated MAS was diagnosed according to the criteria proposed by
Imashuku et al. [24]. s-JIA-associated MAS was diagnosed according to
the criteria proposed by Ravelli et al. [25]. The following criteria were
used to deﬁne the active phase of s-JIA: active arthritis, fever, rash,
hepatosplenomegaly, generalized lymphadenopathy, and serositis, as
well as an increased erythrocyte sedimentation rate and C-reactive
protein (CRP) level. The following criteria were used to deﬁne the
inactive phase of s-JIA while using medication: a lack of clinical symp-
toms observed during the active phase, as well as a normal erythrocyte
sedimentation rate and CRP level. Serum samples were separated from
cells, divided into aliquots, frozen, and stored at−80 °C until further
analysis. This study was approved by the Institutional Review Board at
Kanazawa University, and all specimens were used after the receipt of
informed consent.
The clinical characteristics of patients with active-phase AOSD and
s-JIA are shown in Table 1. Twelve of 27 patients with active AOSD
had not received treatment. The remaining 15 patients were treated
with prednisolone (PSL). One patient was treated with methotrexate
(MTX) in addition to PSL. Forty-seven of 66 patients with s-JIA had not
received treatment. The remaining 19 patients were treated with PSL.
In addition to PSL, four patients were treated with cyclosporine and
two with MTX. No patient had been treated with anti-IL-1 or anti-IL-6
biological drugs at the time of blood collection. The clinical characteris-
tics of patients with MAS are shown in Supplementary Table 1. Two of
six patients with AOSD-associated MAS had not received treatment,
and the remaining four were treated with PSL. Eight of 20 patients
with s-JIA-associatedMAS had not received treatment, and the remain-
ing 12 were treated with PSL. None of these patients had been treated
with anti-IL-1 or anti-IL-6 biological drugs at the time of blood
collection.1.2. Measurement of serum cytokine levels
The serum concentrations of IL-18, IL-6, neopterin, sTNF-RI, and
sTNF-RII were evaluated using commercial enzyme-linked immunosor-
bent assays according to the manufacturer's instructions (IL-18: MBL,
Nagoya, Japan; IL-6, sTNF-RI, and sTNF-RII: R&D Systems, Minneapolis,
MN, USA; neopterin: IBL, Hamburg, Germany). Neopterin, a 2-amino-
4-hydroxy-(1′2′3′-trihydroxypropyl)-pteridine, is produced from
guanosine triphosphate (GTP) via GTP cyclohydrolase I by activated
monocytes/macrophages [26]. The activity of this enzyme is greatly
enhanced by IFN-γ [26]. IFN-γ, which is released by activated type 1
helper T (Th1) lymphocytes and natural killer (NK) cells, is themost po-
tent inducer of neopterin production. Serum TNF-α levels were unde-
tectable. Instead, we measured serum sTNF-RI and -RII levels.
1.3. Statistical analysis
Intra-group comparisons were performed using theMann–Whitney
test or Fisher's exact probability test, where appropriate. A p value
of b0.05 was considered to indicate a signiﬁcant difference.
2. Results
2.1. Serum cytokine proﬁles of patients with AOSD
We determined the serum levels of cytokines, including IL-6, IL-18,
neopterin, sTNF-RI, and sTNF-RII, in patients with AOSD. As shown in
Fig. 1, the serum levels of all evaluated cytokines were elevated in
active-phase patients compared with those in healthy controls.
Furthermore, serum IL-18 levels were markedly elevated even in
patients with inactive-phase disease, whereas other cytokines that
had been elevated during the active phase normalized once patients
had achieved clinical remission. Serum neopterin, IL-18, sTNF-RI, and
sTNF-RII levels were signiﬁcantly higher during the MAS phase than
during the active phase, although IL-6 levels did not differ between
these phases. These ﬁndings were similar to those in patients with
s-JIA (Supplementary Fig. 1).
2.2. Markedly elevated serum IL-18 levels in patients with AOSD and s-JIA
We compared the serum cytokine proﬁles between patients with
AOSD and those with s-JIA (Table 2). Consequently, we used a radar
chart to depict these cytokine proﬁles (Fig. 2). Massively elevated
serum IL-18 levels were a common feature of both active-phase AOSD
and s-JIA (Fig. 2A, D). Signiﬁcant increases in serum neopterin, IL-18,
Fig. 1. Serum cytokine proﬁles of patientswith adult-onset Still's disease (AOSD). Serum concentrations of (A) interleukin (IL)-6, (B) IL-18, (C) neopterin, (D) soluble tumor necrosis factor
receptor type I (sTNF-RI), and (E) sTNF-RII are shown. Bars indicate median values. Statistically signiﬁcant differences between each patient group are indicated as follows: ⁎p b 0.05,
⁎⁎p b 0.01, and ⁎⁎⁎p b 0.001.
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diseases (Fig. 2B, E). Furthermore, the serum IL-18 levels remained
markedly elevated during the inactive phases of both diseases, whereas
other cytokines that were elevated during the active phases normalized
once patients achieved clinical remission (Fig. 2C, F).
As shown in Table 2, the serum IL-18 levels of patients with active
AOSD (95,604 ± 68,089 pg/ml) were signiﬁcantly higher than those
in patients with s-JIA (72,512 ± 84,208 pg/ml; p b 0.05). The serum
neopterin levels in patients with active AOSD (29.0 ± 30.3 nmol/l)
were also signiﬁcantly higher than those in patients with s-JIA
(17.7 ± 17.5 nmol/l; p b 0.05).
2.3. Comparison of the clinical characteristics of AOSD and s-JIA
The clinical characteristics of patients with active-phase AOSD and
s-JIA are shown in Table 1. A signiﬁcant female predominance was
observed among patients with AOSD (p b 0.05). Hepatomegaly andTable 2
Serum cytokine levels in patients with adult-onset Still's disease (AOSD) and systemic ju-
venile idiopathic arthritis (s-JIA) in each disease phase.
AOSD s-JIA p value
Neopterin
(nmol/l)
Active 29.0 ± 30.3 17.7 ± 17.5 0.0127
MAS 83.5 ± 96.5 45.7 ± 26.8 0.4093
Inactive 6.8 ± 4.3 4.4 ± 2.4 0.0545
IL-6
(pg/ml)
Active 36.0 ± 39.2 75.3 ± 147.3 0.4725
MAS 27.2 ± 22.0 51.4 ± 88.5 0.9160
Inactive 3.1 ± 0.3 3.4 ± 1.3 0.7975
IL-18
(pg/ml)
Active 95,604 ± 68,089 72,512 ± 84,208 0.0311
MAS 246,917 ± 136,301 223,665 ± 203,616 0.3604
Inactive 9847 ± 14,613 9320 ± 8549 0.5975
sTNF-RI
(pg/ml)
Active 2790 ± 1154 2956 ± 1600 0.9440
MAS 5493 ± 2897 3866 ± 1712 0.2289
Inactive 1051 ± 339.3 1033 ± 487.5 0.5165
sTNF-RII
(pg/ml)
Active 12,920 ± 10,905 9967 ± 8406 0.1195
MAS 32,683 ± 18,617 22,842 ± 11,399 0.2795
Inactive 3168 ± 1138 2916 ± 1500 0.4862splenomegaly were observed signiﬁcantly more frequently with AOSD
(p b 0.05). In contrast, arthritis was observed signiﬁcantly more
frequently with s-JIA than with AOSD (p b 0.05). Serum ferritin levels
were signiﬁcantly higher in patients with AOSD than in those with
s-JIA (p b 0.05).
2.4. Distinct clinical features of the two subgroups of patients with AOSD
based on serum IL-6 and IL-18 levels
As shown in Fig. 3, patients with AOSD could be divided into two
subgroups based on their serum IL-6 and IL-18 levels: IL-6-dominant
(IL-18/IL-6 b 5000; n = 16) and IL-18-dominant (IL-18/IL-6 N 5000;
n = 11). As shown in Table 3, the serum IL-6 levels were signiﬁcantly
higher in the IL-6-dominant subgroup (mean ± standard deviation:
53.3 ± 42.8 pg/ml) than in the IL-18-dominant subgroup (10.8 ±
9.4 pg/ml; p b 0.001). In contrast, serum IL-18 levels were higher in
the IL-18-dominant subgroup (129,809 ± 71,023 pg/ml) than in the
IL-6-dominant subgroup (72,088 ± 56,790 pg/ml), although this
difference was not statistically signiﬁcant. In addition, serum ferritin
levels were signiﬁcantly higher in the IL-18-dominant subgroup
(21,348 ± 37,947 pg/ml) than in the IL-6-dominant subgroup
(3989 ± 6140 pg/ml; p b 0.05).
Next, we compared the clinical features of each subgroup (Table 3).
The number of patients with arthritis was signiﬁcantly higher in the
IL-6-dominant subgroup than in the IL-18-dominant subgroup
(p b 0.05). No patient in the IL-18-dominant subgroup presented with
arthritis.
3. Discussion
AOSD has been regarded as the adult manifestation of a disease
spectrum that includes s-JIA. Similarities in the clinical and laboratory
features of both diseases suggest that similar pathogenic mechanisms
might underlie the development of these entities. Recently, the charac-
terization of autoinﬂammatory diseases has led to a renewed classiﬁca-
tion of immune-mediated rheumatic diseases [27]. Recent reports
Fig. 2. Serum cytokine proﬁles and radar charts of patients with adult-onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (s-JIA) during each disease phase.
Representative proﬁles of serum cytokines, including neopterin, interleukin (IL)-6, IL-18, soluble tumor necrosis factor receptor type I (sTNF-RI), and sTNF-RII are shown.
Table 3
Clinical features of two subgroups of patients with adult-onset Still's disease based on se-
rum interleukin (IL)-6 and IL-18 levels.
F: female; M: male.
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autoinﬂammatory diseases that follow the same continuum as AOSD
[12,28,29]. However, whether s-JIA and AOSD are the same disease
remains controversial.
In the present study, we observed similar cytokine release patterns
in both clinical entities, characterized by a common signiﬁcant increase
in IL-18 expression. Notably, the serum IL-18 levels were markedly in-
creased in both patients with s-JIA and those with AOSD. Interestingly,
the serum IL-18 levels of patients with both diseases remained elevated
relative to control levels, even in patients with inactive-phase disease.
These ﬁndings suggest that abnormal IL-18 production is highly
characteristic of both s-JIA and AOSD.Fig. 3. Distinct subgroups of patients with adult-onset Still's disease (AOSD) based on
serum interleukin (IL)-6 and IL-18 levels. Patients with arthritis are represented by red
circles.IL-18 plays an important role in the regulation of NK cell activity.
Previous reports described reduced NK cell function in patients with
s-JIA and AOSD [30–33]. The mechanism underlying impaired NK cell
function in patients with s-JIA has been associated with a defect in
IL-18 receptor β phosphorylation [34]. Another report found that an im-
balance between IL-18 and its natural inhibitor, IL-18-binding protein,









Age 46.8 ± 15.9 51.6 ± 19.4 0.5849
Sex(M/F) 4/12 2/9 1.0000
Clinical features
Rash 11 (69) 8 (73) 1.0000
Arthralgia 14 (88) 7 (64) 0.1874
Lymphadenopathy 5 (31) 7 (64) 0.1302
Liver dysfunction 7 (44) 9 (82) 0.1090
Sore throat 5 (31) 4 (36) 1.0000
Myalgia 2 (13) 1 (9) 1.0000
Hepatomegaly 9 (56) 2 (18) 0.1090
Splenomegaly 6 (38) 6 (55) 0.6924
Arthritis 7 (44) 0 (0) 0.0216
Laboratory data
hyperleukocytosis 13 (81) 7 (64) 0.3913
Ferritin (ng/ml) (n =
22)
3989 ± 6140 21,348 ± 37,947 0.0304
IL-6 (pg/ml) 53.3 ± 42.8 10.8 ± 9.4 0.0005
IL-18 (pg/ml) 72,088 ± 56,790 129,809 ± 71,023 0.0564
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thus might have allowed the development of secondary
hemophagocytic syndrome [35]. We previously reported that an infant
born to a mother with active AOSD and high serum IL-18 levels exhibit-
ed persistently decreased NK cell function [36]. However, this NK cell
dysfunction recovered as the infant's serum IL-18 levels decreased
[36]. Furthermore, we recently reported a signiﬁcant increase in
serum IL-18 levels during the active phase in patients with MAS
compared with those without MAS [19]. These ﬁndings indicate that a
nonfunctional IL-18/NK cell axis, induced by sustained high serum
IL-18 levels, might be closely related to MAS development in both
s-JIA and AOSD. Thus, IL-18 might play a key role in the complex
network underlying inﬂammation in patients with s-JIA and AOSD.
In this study, serum IL-18 levels were signiﬁcantly higher in patients
with active AOSD than in those with s-JIA. This result was comparable
with those of previous studies conducted on Japanese patients [21,37].
Serum neopterin levels were also signiﬁcantly higher in patients with
active AOSD than in those with s-JIA. Cytokine production develops in
an age-dependentmanner [38]. Therefore, pediatric immunological im-
maturitymight account for the differences in serum IL-18 and neopterin
levels observed between patients with s-JIA and AOSD.
Previous studies that compared the clinical features and laboratory
ﬁndings of s-JIA and AOSD revealed that these two entities share
many common characteristics and might actually represent the same
clinical spectrum, thus differing only in age distribution [3–6]. In sup-
port of this view, the present study found no differences between
these conditions except for hepatomegaly and splenomegaly, which
were more frequently observed in AOSD, and arthritis, which was
more frequently observed in s-JIA. Previous studies reported signiﬁcant
differences between s-JIA and AOSD with regard to the frequencies of
fever, skin rash, and sore throat, all of which occurred more frequently
with AOSD [3,6]. The enrollment of more pediatric patients in our
study relative to previous studies on clinical disease expression might
account for the observed discrepancies. Furthermore, the diagnostic
criteria of s-JIA include thepresence of arthritis. However, some patients
whopresentwith systemic features characteristic of s-JIA never develop
arthritis. These ﬁndings might also explain the signiﬁcantly increased
frequency of arthritis in patients with s-JIA compared with those in pa-
tients with AOSD. In addition to clinical symptoms, most laboratory ab-
normalities were common to both patients with s-JIA and those with
AOSD. However, serum ferritin levels were signiﬁcantly higher in pa-
tients with AOSD than in those with s-JIA [5,6]. These ﬁndings were
comparablewith those of previous studies. Furthermore, 26%of patients
with s-JIA in this study developed MAS. This was in line with recent re-
ports [39,40] rather than with an older report [41].
In addition to IL-18, increased serum IL-6 levels were also observed
in patients with s-JIA and AOSD. In reports on both conditions, serum
IL-6 levels have been correlatedwith speciﬁcmarkers of disease activity,
including joint involvement, skin rash, pyrexia, CRP and ferritin levels,
elevated liver enzymes, and leukocytosis [42–47]. Macrophages and en-
dothelial cells are themain sources of IL-6, a cytokine that is responsible
not only for the production of acute-phase proteins by hepatocytes, but
also for hyperferritinemia, characterized by the uptake of free iron and
ferritin synthesis [48,49]. Furthermore, IL-6 is also closely related to
the development of arthritis in both s-JIA and AOSD. Previous reports
have demonstrated a correlation between serum IL-6 levels and arthri-
tis severity in patients with s-JIA [46] and rheumatoid arthritis [50].
Biological agents that inhibit innate inﬂammatory cytokines (specif-
ically, IL-1 and IL-6) have induced a paradigm shift in s-JIA treatment
[14,15,51]. The inhibition of IL-1 or IL-6 is highly efﬁcacious inmany pa-
tients with s-JIA, yielding improvements in both systemic symptoms
and arthritis [52,53]. Furthermore, recent studies demonstrated the
identiﬁcation of two subgroups of s-JIA with distinct clinical features
[19,52,53]. In the present study, we demonstrated the similar existence
of two subgroups of patients with AOSD and certain distinct clinical fea-
tures that could be distinguished based on IL-6 and IL-18 levels.Interestingly, a recent study reported the existence of two subgroups
of patients with AOSD that were based on serum IL-18 levels [54]. Pa-
tients with severe systemic inﬂammatory disorders (non-RA subtype)
presented with high IL-18 levels, whereas those that developed severe
arthritis (RA subtype) presented with low IL-18 levels [54]. The present
study ﬁndings were consistent with those earlier ﬁndings and indicate
that s-JIA and AOSD might be pathogenically identical.
Some patients with s-JIA and AOSD were treated with steroids and/
or immunosuppressive drugs at the time of blood collection, thus
representing a potential limitation of this study. Speciﬁcally, these
drugs might have affected cytokine production.
Despite this limitation, as expected, our results suggest that the
patterns of cytokine release in s-JIA and AOSD share common features,
including a signiﬁcant increase in IL-18 production. Abnormal IL-18pro-
duction appears to be characteristic of both s-JIA and AOSD. Further-
more, distinct cytokine proﬁles based on IL-6 and IL-18 production
might be responsible for the distinct clinical expression patterns. The
presence of two distinct subgroups among patients with both diseases
further supports the view that s-JIA and AOSD belong to the same
disease category.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.clim.2016.05.010.
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